ArticleOncogene2005
Future prospects for oncolytic therapy.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.International journal of medical sciences · 2021Review
- Computational modeling approaches to the dynamics of oncolytic viruses.Wiley interdisciplinary reviews. Systems biology and medicine · 2016Review
- Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches.PLoS computational biology · 2012Article
- Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.Human gene therapy · 2011Article
- Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.Human gene therapy · 2010Article
- The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.Oncogene · 2010Article
- ODE models for oncolytic virus dynamics.Journal of theoretical biology · 2010Article
- A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.Cancer gene therapy · 2010Article
- Use of oncolytic viruses for the eradication of drug-resistant cancer cells.Journal of the Royal Society, Interface · 2009Article
- Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.PloS one · 2009Article
- Article
- Targeting the absence: homozygous DNA deletions as immutable signposts for cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.
Indexed as
Identifiers
16299540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.